Search results for "far"

showing 10 items of 6421 documents

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design

2019

Abstract Introduction and objectives Although clinical guidelines recommend invasive management in non–ST-segment elevation myocardial infarction (NSTEMI), this strategy is underused in frail elderly patients in the real world. Furthermore, these patients are underrepresented in clinical trials and therefore the evidence is scarce. Our hypothesis is that an invasive strategy will improve prognosis in elderly frail patients with NSTEMI . Methods This will be a prospective, multicenter, randomized trial, in which the conservative and invasive strategies will be compared in patients meeting all of the following inclusion criteria: NSTEMI diagnosis, age ≥ 70 years, and frailty defined by a cate…

medicine.medical_specialtymedicine.medical_treatmentFrail ElderlyAcute myocardial infarction030204 cardiovascular system & hematologyRevascularizationConservative TreatmentCoronary Angiographylaw.invention03 medical and health sciences0302 clinical medicineElderlyRandomized controlled triallawmedicineClinical endpointMyocardial RevascularizationHumansMulticenter Studies as TopicFrail elderlyMyocardial infarctionProspective StudiesProspective cohort studyNon-ST Elevated Myocardial InfarctionAgedRandomized Controlled Trials as TopicFrailtybusiness.industryGeneral Medicinemedicine.diseaseClinical trialTreatment OutcomeSample size determinationSample SizeEmergency medicinebusiness
researchProduct

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct

No difference in 30-day outcome and quality of life in transradial versus transfemoral access – results from the German Austrian ABSORB registry (GAB…

2021

Abstract Background Radial (RA) instead of femoral access (FA) for coronary interventions has become a European Society of Cardiology Class-IA guideline recommendation. But when the decision on the access site is left to the discretion of the operator, differences in adverse event rates mitigate. Methods We compared the 30-day outcome for RA and FA in all patients recruited for the observational German Austrian ABSORB Registry (GABI-R) in regard to all-cause mortality, stroke, myocardial infarction (MI), TIMI major bleedings (TMB) and quality of life (QoL). All patients were treated with a bioresorbable vascular scaffold. Access site was left to the discretion of the operator. Results In to…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionHemorrhagePercutaneous Coronary InterventionQuality of lifemedicineHumansMyocardial infarctionRegistriesStrokebusiness.industryPercutaneous coronary interventionGeneral MedicineGuidelinemedicine.diseaseFemoral ArteryStrokeTreatment OutcomeAustriaEmergency medicineCohortConventional PCIRadial ArteryQuality of LifeCardiology and Cardiovascular MedicinebusinessTIMI
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct

Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up

1987

Ninety-one patients with acute myocardial infarction were assigned to intravenous treatment with streptokinase or rt-PA as part of the randomized trial carried out by the European Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). A patent coronary artery was found in 37 of 45 (82%) patients treated with rt-PA and in 27 of 46 (59%) patients treated with streptokinase 75-90 minutes after start of infusion. Patients were subsequently anticoagulated with heparin or dicoumarol up to a repeat angiography 3 weeks after the infarction. Of the 64 patients with successful reperfusion, 3 died and 3 suffered reocclusion of the vessel. Quantitative analysis of the coronary stenosis …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseInfarctionCoronary DiseaseCoronary AngiographyRandom AllocationReperfusion therapyRecurrenceInternal medicineHumansMedicineStreptokinaseMyocardial infarctionVascular PatencyClinical Trials as Topicmedicine.diagnostic_testbusiness.industryHeparinThrombolysisMiddle Agedmedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureTissue Plasminogen ActivatorAngiographyCardiologyCineangiographyRadiographic Image Interpretation Computer-AssistedCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugArteryEuropean Heart Journal
researchProduct

Multivessel Intervention in Myocardial Infarction with Cardiogenic Shock: CULPRIT-SHOCK Trial Outcomes in the PL-ACS Registry

2021

Background: The aim of the study was a comparison of culprit-lesion-only (CL-PCI) with the multivessel percutaneous coronary intervention (MV-PCI) in terms of 30-day and 12-month mortality in a national registry. Methods: Patients from the PL-ACS registry with MI and CS were analyzed. Patients meeting the criteria of the CULPRIT-SHOCK trial were divided into two groups: CL-PCI and MV-PCI groups. Results: Of the 3265 patients in the PL-ACS registry with MI complicated by CS, the criteria of the CULPRIT-SHOCK trial were met by 2084 patients (63.8%). The CL-PCI was performed in 883 patients, and MV-PCI was performed in 1045 patients. After the propensity score matching analysis, 617 well-match…

medicine.medical_specialtymedicine.medical_treatmentacute myocardial infarction030204 cardiovascular system & hematologyRevascularizationacute myocardial infarction; cardiogenic shock; percutaneous coronary interventionCulpritArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinecardiovascular diseases030212 general & internal medicineMyocardial infarctionbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseasesurgical procedures operativemedicine.anatomical_structureShock (circulatory)Propensity score matchingMedicinemedicine.symptombusinessArteryJournal of Clinical Medicine
researchProduct

Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

2021

The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open sur…

medicine.medical_specialtymedicine.medical_treatmentaortic valve stenosis030204 cardiovascular system & hematologyTAVRnew-generation trans-catheter heart valvesProsthesisArticle03 medical and health sciences0302 clinical medicineValve replacementInternal medicinemedicine030212 general & internal medicineMyocardial infarctionStrokeEjection fractionbusiness.industryRGeneral Medicinemedicine.diseaseStenosisAortic valve stenosisCardiologyMedicineImplantbusinesslong-term outcomesJournal of Clinical Medicine
researchProduct

Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and o…

2014

Background: Ischemic postconditioning (PCON) appears as a potentially beneficial tool in ST-segment elevation myocardial infarction (STEMI). We evaluated the effect of PCON on microvascular obstruction (MVO) in STEMI patients and in an experimental swine model. Methods: A prospective randomized study in patients and an experimental study in swine were carried out in two university hospitals in Spain. 101 consecutive STEMI patients were randomized to undergo primary angio-plasty followed by PCON or primary angioplasty alone (non-PCON). Using late gadolinium enhancement cardiovascular magnetic resonance, infarct size and MVO were quantified (% of left ventricular mass). In swine, using an ang…

medicine.medical_specialtymedicine.medical_treatmentlaw.inventionTECNOLOGIA ELECTRONICARandomized controlled triallawInternal medicineAngioplastymedicineIn patientMyocardial infarctioncardiovascular diseasesIschemic postconditioningEjection fractionmedicine.diagnostic_testExperimental modelbusiness.industryIschemic postconditioning Myocardial infarction PerfusionMagnetic resonance imagingmedicine.diseasePerfusionMyocardial infarctionsurgical procedures operativeCardiologyCardiology and Cardiovascular MedicinebusinessPerfusion
researchProduct

Materiell og profesjonell stigmatisering av mennesker med sykelig overvekt

2017

The aim of this study is to show how people suffering from severe obesity mightexperience stigmatization. We interviewed 6 persons recruited from aNorwegian rehabilitation center, specialized in lifestyle intervention in severeobesity. We found that the participants suffering from severe obese experiencedstigmatization and thus felt that they a) did not fit into the materiel world and b)experienced a lack of respect from health care professionals. The results arediscussed according to how contemporary symbols are embedded in oursurroundings and in our bodies. The conclusion underlines severe obesity as acomplex problem which is strengthened by rooms and interior designed for idealsizes. The…

medicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectsevere obesityeducationStigma (botany)Norwegianmacromolecular substancesself-experiencematerial surroundingsHealth careLifestyle interventionmedicinePsychiatrymedia_commonlcsh:RT1-120Rehabilitationlcsh:Nursingbusiness.industryegenerfaringPsykisk helsearbeidSevere obesityHealth professionslanguage.human_languageFeelingstigmalanguageself-experience; health professions; material surroundings; severe obesity; stigma;egenerfaring; helsepersonell; materielle omgivelser; sykelig overvekt; stigmahealth professionsbusinessNordisk Tidsskrift for Helseforskning
researchProduct